What is AdVac® technology?

AdVac® technology involves the development and manufacture of novel vectors (gene transport vehicles) made from adenoviruses (harmless cold viruses) that very rarely infect humans, such as AD35. Genetic material encoding for viruses, parasites or bacteria can be inserted into these vectors to make novel vaccines against a broad range of human pathogens, or the vectors can be used to make gene therapy products.

Key strengths

• AdVac® technology is a powerful vector system, especially when coupled with PER.C6® technology, which unlike any other cell line does not allow replication-competent adenoviruses to form during the production of replication-deficient vectors.
• AdVac® technology is based on adenoviruses that very rarely infect humans, whereas other adenovirus vectors are based on viruses that are widespread in human populations—and therefore much more likely to encounter pre-existing immunity. By circumventing pre-existing immune responses against the adenovirus vector, AdVac®-based vaccines allow accurate dose control and are potentially more effective than other adenoviral vector vaccines.
• AdVac®-based vectors share the advantages of the widely used adenovirus vectors, such as scalable production, high yields and the ability to mediate a strong T-cell immune response.